New use of Panax Notoginseng and aspirin combination

A technology of aspirin and combined application, applied in the new use field of combination or combination of Panax notoginseng and aspirin, to achieve good effects and reduce gastric mucosal damage

Active Publication Date: 2018-03-30
INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no in-depth study on the mechanism of Panax notoginseng saponins for cardiovascular and cerebrovascular diseases, and there is no discovery and creation of combined application with antiplatelet drugs such as aspirin. Synergize the use effect of reducing toxicity, improve its effectiveness, and provide a safer and more effective drug combination and use method for clinical treatment and prevention of cardiovascular and cerebrovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of Panax Notoginseng and aspirin combination
  • New use of Panax Notoginseng and aspirin combination
  • New use of Panax Notoginseng and aspirin combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: The synergistic effect of combined use of Panax notoginseng saponins and aspirin on myocardial ischemia-reperfusion injury in rats.

[0023] 1. Test animals

[0024] Healthy male SD rats (body weight 280-300 g) were provided by Beijing Weitong Lihua Experimental Animal Company, and were raised in the Animal Center of the Institute of Medicinal Botany, Chinese Academy of Medical Sciences. Animals were fed adaptively for 1 week before testing. Before the experiment was carried out, it was reviewed and approved by the Experimental Animal Management and Animal Welfare Committee of the Institute of Medicinal Plants, Chinese Academy of Medical Sciences / Peking Union Medical College.

[0025] 2. Test method

[0026] 2.1 Animal grouping and drug treatment

[0027] 240 male SD rats were randomly divided into 8 groups, 30 in each group, respectively: sham operation group, myocardial ischemia-reperfusion injury model group, Panax notoginseng saponins (50mg / kg) group, ...

Embodiment 2

[0044] Example 2: The synergistic effect of combined use of Panax notoginseng saponins and aspirin on cerebral ischemia-reperfusion injury in rats.

[0045] 1. Test animals

[0046] Healthy male SD rats were provided by Beijing Weitong Lihua Experimental Animal Company and raised in the Animal Center of Institute of Medicinal Botany, Chinese Academy of Medical Sciences. Animals were fed adaptively for 1 week before testing. Before the experiment was carried out, it was reviewed and approved by the Experimental Animal Management and Animal Welfare Committee of the Institute of Medicinal Plants, Chinese Academy of Medical Sciences / Peking Union Medical College.

[0047] 2. Test method

[0048] 2.1 Animal grouping and drug treatment

[0049] 240 male SD rats were randomly divided into 8 groups, 30 in each group, respectively: sham operation group, middle cerebral artery embolism (MCAO / R) model group, Panax notoginseng saponins (50mg / kg) group, aspirin (10mg / kg) group, aspirin...

Embodiment 3

[0087]Example 3: Panax notoginseng saponins can inhibit aspirin-induced gastrointestinal mucosal damage

[0088] 1. Test animals

[0089] Healthy male SD rats (body weight 280-300 g) were provided by Beijing Weitong Lihua Experimental Animal Company, and were raised in the Animal Center of the Institute of Medicinal Botany, Chinese Academy of Medical Sciences. Animals were fed adaptively for 1 week before testing. Before the experiment was carried out, it was reviewed and approved by the Experimental Animal Management and Animal Welfare Committee of the Institute of Medicinal Plants, Chinese Academy of Medical Sciences / Peking Union Medical College.

[0090] 2. Test method

[0091] 2.1 Animal grouping and drug treatment

[0092] 40 male SD rats were randomly divided into 4 groups, 10 in each group, respectively: blank control group, aspirin (10mg / kg) group, Panax notoginseng saponins (100mg / kg)+aspirin (10mg / kg) group, Panax notoginseng total saponins (100mg / kg) group. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a Panax Notoginseng and aspirin combination in the prevention and treatment of cardiovascular and cerebrovascular diseases. The combination comprises 25-500 mg / d of Panax Notoginseng total saponins and 20-700 mg / d of aspirin. The Panax Notoginseng contains a commercially available product Panax Notoginseng medicinal material, Panax Notoginseng extract, Panax Notoginseng effective components and Panax Notoginseng preparations, and the Panax Notoginseng and the aspirin have synergistic effects to achieve the prevention and treatment of the cardiovascularand cerebrovascular diseases and alleviate aspirin induced gastric mucosal damages in rats.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines, and in particular relates to the combination or combined application of Panax notoginseng and chemical drug aspirin in the prevention and treatment of heart and cerebrovascular diseases, and in particular to the preparation of various medicinal materials such as roots, cuts, tendons, stems and leaves of Panax notoginseng. finished product), Panax notoginseng extract, effective parts of Panax notoginseng and its preparation and aspirin in the prevention and treatment of cardiovascular and cerebrovascular diseases, and at the same time reduce the gastric mucosal damage caused by aspirin in rats, reduce the risk of bleeding, and show synergistic and attenuated toxicity role. Background technique [0002] Secondary prevention of cardiovascular and cerebrovascular diseases refers to the early detection, early diagnosis and early treatment of patients with coronary heart disease, cerebral i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/258A61P9/00A61P9/10A61P25/00A61P1/04A61K31/616
CPCA61K31/616A61K36/258A61K2300/00
Inventor 孙晓波孟祥宝孙桂波徐惠波
Owner INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap